| Ytd | -17.89% | |
| 1y | -5.04% |
| Open | 3.54 | Prev Close | 3.53 | Low | 3.51 | High | 3.58 | Mkt Cap | 137.24M |
| Vol | 1.75K | Avg Vol | 1.53K | EPS | -1.68 | P/E | N/A | Forward P/E | -2.96 |
| Beta | 0.54 | Short Ratio | 4.49 | Inst. Own | 5.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-25 | 50-d Avg | 4.02 | 200-d Avg | 4.17 | 1yr Est | 10.37 |
MOLN News
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.38) per share which beat the analy
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
Molecular Partners (NASDAQ: MOLN - Get Free Report) and Coherus Oncology (NASDAQ: CHRS - Get Free Re
Vertex Pharmaceuticals (NASDAQ: VRTX - Get Free Report) and Molecular Partners (NASDAQ: MOLN - Get F
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the ana
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving preci
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partne
Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosi
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712Dosing ongoing
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIR
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. , May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partner
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.45) per share which missed the ana
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announceme
ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partner
MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast a
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a B
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MS
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MS
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announce
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partn
Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partn
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partn
HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a B
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.41) per share which missed the ana
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schliere
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical deve
HC Wainwright & Co. analyst Robert Burns initiates coverage on Molecular Partners (NASDAQ:MOL
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, ini
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lo
Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccel
Case study with first patient images of half-life engineered MP0712 from compassionate care use show
Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate t
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(1.65) per share which missed the ana
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lo
In H1 2025, Molecular Partners undertook a strategic review of its operations and headcount, with th